Global Poractant Alfa Market Size, Share, and Trends Analysis Report, By Type (Rapid Dosing and Microdosing), By Application (Salvage Treatment and Prevention of Respiratory Distress Syndrome (RDS), Forecast (2022-2028)

The global poractant alfa market is anticipated to grow at a CAGR of 3.0% during the forecast period (2022- 2028). Poractant alfa is a lung surfactant which is a pharmaceutical drug that is used to prevent or treat respiratory distress syndrome (RDS) in newborns. It belongs to the drug group of medicines known as surfactants which are found naturally on the surface of lung cells. Surfactant is sold under the brand name Curosurf by Chiesi Farmaceutic. As with other surfactants, a marked improvement in oxygenation may occur within minutes of the administration of protectant alfa. The increase in incidences rate of respiratory distress syndrome (RDS) in infants is the major factor that is driving the growth of the market.

The market is segmented based on the type and application. Based on the type, the market is sub-segmented into rapid dosing and microdosing. Rapid dosing is used to reduce the risk of respiratory distress syndrome (RDS) in newborns. This drug comes as a liquid and must be added directly into the umbilical cord vein within minutes after birth. Micro dosing means taking a very small dose of some popular hallucinogenic substances. It is given through an endotracheal tube, which delivers it slowly over time through an intravenous pump. In micro-dosing, the use of poractant alfa reduces or delays the need for mechanical ventilation therapy and duration of hospitalization without any adverse effects on mortality rates.

Based on the application, the market is sub-segmented into salvage treatment and prevention of respiratory distress syndrome (RDS). The drug support to keep open collapsed passages, known as ducts, by reducing the surface tension between gas-filled spaces and fluid-filled areas. In respiratory distress syndrome (RDS) poractant alfa can be used for treating newborn infants who are born before 31 weeks earlier or weigh less than 17 pounds with earlier age younger than 29 weeks. Some major companies in the market include Takeda Pharmaceutical Co. Ltd., Mylan NV, and Douglas Pharmaceuticals Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships, new product launches, and collaborations, to stay competitive in the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Takeda Pharmaceutical Co. Ltd., Mylan NV, and Douglas Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Poractant Alfa Market Report by Segment

By Type

• Rapid Dosing
• Microdosing

By Application        

• Salvage Treatment
• Prevention of Respiratory Distress Syndrome (RDS)

Global Poractant Alfa Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa